Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 TCR Gene Therapy for Leukemia: Phase I/II Safety and Toxicity Study
2006-004950-25Phase 2Completed
- Sponsor
- Kuur Therapeutics
- Start
- Nov 2008
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 TCR transduced T cells in acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML), sponsored by Kuur Therapeutics. Primary endpoint: PRIMARY ENDPOINTS AND OUTCOME MEASURES. Started Nov 2008; status: completed.
02
Drugs
WT1 TCR transduced T cells
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2006-004950-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004950-25.